Shares of orphan drugmaker NPS Pharmaceuticals (NASDAQ:NPSP) are up more than 4% in intraday trading. The company, which gained Food and Drug Adminstration approval for its short bowel syndrome drug Gattex back in December, reported its first-quarter earnings and revealed the prescription numbers and sales of its drug launch. In the following video, health care analyst Max Macaluso discusses these details and three key takeaways from the company's first quarter.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why NPS Pharmaceuticals, Inc. Shares Soared 28% in January
NPS Pharmaceuticals' stock lifts off in January after a double-dose of good news.
The Surprising Thing Most of 2014's Top 10 Stocks Have in Common
8 out of 10 of last year's best-performing stocks have this one important common denominator.
3 Biotech Stocks That Could Double in 2015
Three Motley Fool contributors tell us which biotech stocks they think could make a big move next year.